最准的六合彩论坛

The trial, which at 最准的六合彩论坛H is led by consultant haematologist Dr Mallika Sekhar, is applying a treatment approach known as immunomodulation 鈥� aimed at dampening the overactive immune response seen among hospitalised Covid-19 patients 鈥� and is in line with 最准的六合彩论坛H鈥檚 interest in this approach.

Ruxolitinib is a well-established drug which inhibits the action of聽cytokines聽that are responsible for聽an overreaction of the immune system聽called cytokine release syndrome (CRS).

Many patients with severe respiratory (lung) disease due to Covid-19 have features consistent with the CRS, so it is thought that ruxolitinib might also help in Covid-19.

In the trial 鈥� sponsored by Novartis 鈥� patients diagnosed with Covid-19 pneumonia will be given the drug while they continue to receive the current standard of care. Out of every 3 patients enrolled, two will be randomly assigned to receive ruxolitinib (active) and one will be randomly assigned to receive a placebo (no active drug).

最准的六合彩论坛H has recruited its first patient to the study, though recruitment to the study is challenging because of strict criteria around who is eligible for the trial 鈥� and due to the welcome fall in the number of Covid patients hospitalised at 最准的六合彩论坛H since the peak in cases.

After a screening period of assessments, eligible patients take a single tablet twice a day for 14 days. After聽that the聽treatment can be extended by a further 14 days if needed. Patients are in the study for a maximum of 29 days.

Dr Sekhar said: 鈥淲e will be looking at the proportion of patients who go on to聽develop respiratory failure,聽whether they need to be admitted to the intensive care unit during their hospital stay and the proportion聽of patients who succumb to Covid-19. Based on what we know about the drug, there is good reason to believe it will be聽of benefit聽in Covid-19, and we hope to be able to demonstrate this.鈥�